TR200101149T2 - Dış retina bozukluklarının tedavisi. - Google Patents

Dış retina bozukluklarının tedavisi.

Info

Publication number
TR200101149T2
TR200101149T2 TR2001/01149T TR200101149T TR200101149T2 TR 200101149 T2 TR200101149 T2 TR 200101149T2 TR 2001/01149 T TR2001/01149 T TR 2001/01149T TR 200101149 T TR200101149 T TR 200101149T TR 200101149 T2 TR200101149 T2 TR 200101149T2
Authority
TR
Turkey
Prior art keywords
treatment
retinal disorders
external retinal
external
disorders
Prior art date
Application number
TR2001/01149T
Other languages
English (en)
Inventor
Robert J. Collier, Jr.
R. Hellberg Mark
A. Kapin Michael
E. Barnes George
L. Chandler Michael
Original Assignee
Alcon Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc. filed Critical Alcon Laboratories, Inc.
Publication of TR200101149T2 publication Critical patent/TR200101149T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Dis retina bozukluklarinin, glutamat antagonistleriyle tedavi edilmesi için bilesimler ve bu bilesimlerin kullanilmasi açiklanmistir.
TR2001/01149T 1998-10-27 1999-10-20 Dış retina bozukluklarının tedavisi. TR200101149T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10571298P 1998-10-27 1998-10-27

Publications (1)

Publication Number Publication Date
TR200101149T2 true TR200101149T2 (tr) 2001-10-22

Family

ID=22307389

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01149T TR200101149T2 (tr) 1998-10-27 1999-10-20 Dış retina bozukluklarının tedavisi.

Country Status (12)

Country Link
US (1) US6509355B1 (tr)
EP (1) EP1126850A4 (tr)
JP (1) JP2002528416A (tr)
KR (1) KR20020002356A (tr)
CN (1) CN1324240A (tr)
AR (1) AR023687A1 (tr)
AU (1) AU761824B2 (tr)
BR (1) BR9914848A (tr)
CA (1) CA2347863C (tr)
TR (1) TR200101149T2 (tr)
WO (1) WO2000024396A1 (tr)
ZA (1) ZA200103236B (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
CA2295098A1 (en) * 1997-06-30 1999-01-07 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
JP2002182418A (ja) * 2000-12-11 2002-06-26 Konica Corp 画像形成方法、画像形成装置
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
FR2822706A1 (fr) * 2001-03-29 2002-10-04 Univ Pasteur Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050283109A1 (en) * 2003-03-07 2005-12-22 Peyman Gholam A Method and apparatus for lacrimal canal obstruction
US7220224B1 (en) * 2003-03-07 2007-05-22 Minu, Llc Retinal translocation and fixation using adhesive material
US20050130878A1 (en) * 2003-11-26 2005-06-16 Alcon, Inc. Prevention of photic injury by administering a TACE inhibitor
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
WO2008098027A2 (en) * 2007-02-06 2008-08-14 Allergan, Inc. Treatment of ischemic retinal conditions with memantine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
FR2717080B1 (fr) * 1994-03-09 1996-12-13 Synthelabo Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
CZ66598A3 (cs) 1995-09-08 1998-06-17 Synthelabo Deriváty 4-(cykloalkyl)piperidinů a 4-(cykloalkylalkyl)-piperidinů, způsob jejich přípravy a léčivo, které je obsahuje
FR2738567B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de alpha-phenylpiperidine-1-propanol, leur preparation et leur application en therapeutique
JP2000507205A (ja) * 1996-01-02 2000-06-13 シンテラボ 眼の虚血障害の治療薬の製造のためのポリアミン部位拮抗物質の使用
CA2295098A1 (en) * 1997-06-30 1999-01-07 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy

Also Published As

Publication number Publication date
EP1126850A4 (en) 2003-01-15
BR9914848A (pt) 2001-07-10
CA2347863A1 (en) 2000-05-04
KR20020002356A (ko) 2002-01-09
AU1516900A (en) 2000-05-15
WO2000024396A1 (en) 2000-05-04
JP2002528416A (ja) 2002-09-03
EP1126850A1 (en) 2001-08-29
US6509355B1 (en) 2003-01-21
CN1324240A (zh) 2001-11-28
ZA200103236B (en) 2001-10-23
CA2347863C (en) 2009-05-05
WO2000024396A9 (en) 2000-09-28
AU761824B2 (en) 2003-06-12
AR023687A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
ATE413192T1 (de) Die vorbeugung und behandlung von netzhautischämie und ödem
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
HK1051005A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60219961T8 (de) Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
TR200402628T4 (tr) Androjenetik ve yaygın alopezinin tedavisinde melatonin maddesinin kullanımı
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
DE69621799D1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
DK1000046T3 (da) Piperazinderivater, der er aktive på den nedre urinvejskanal
DK0871446T3 (da) Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve
DE60327335D1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
PT1140080E (pt) Utilizacao de riluzole no tratamento de traumatismos acusticos
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması
DE69730515D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
TR200000916T2 (tr) İkameli piperidin türevleri.